BCG immunotherapy against superficial bladder carcinoma recurrences is regarded as the most successful to date. However, the mode of action has not yet been fully explained. In this field, several European groups have recently significantly contributed by adding more details to the complex picture of the immunological processes of BCG effector mechanisms. BCG inflammation obviously differs from non-specific inflammation by its quality and subclinical duration. Infiltration of immunocompetent cells into the bladder wall with secretion of cytokines into the urine has been characterized. Specific humoral responses of patients towards mycobacterial antigens have been determined. These data clearly present a large body of evidence that the inflammatory reaction induced by BCG correlates with the anti-tumour response. In vitro models of cytotoxic effector cells have shown interesting and selective effector mechanisms induced by BCG. Animal models have proven valuable in supporting ex vivo and in vitro data and in clarifying new aspects of the application of BCG in vivo. Future research efforts will certainly add understanding to the immediate and long-term humoral and cellular responses. All our investigations intend to define clearly surrogate parameters for efficacy and side-effects, to increase therapeutic efficacy further and to decrease side-effects associated with this therapy. Only the collaborative efforts of several groups will be able to achieve a highly effective immunotherapeutic regimen against bladder carcinoma.

1.
Old LJ, Clarke DA, Benacerraf B: Effect of bacillus Calmette-Guérin infection on transplanted tumors in the mouse. Nature 1959;184:291–292.
2.
Zbar B, Rapp HJ: Immunotherapy of guinea pig cancer with BCG. Cancer 1974;34:1532–1540.
3.
Zbar B, Bernstein ID, Rapp HJ: Suppression of tumor growth at the site of infection with living BCG. J Natl Cancer Inst 1971;46:831–839.
4.
Hanna MG, Zbar B, Rapp HJ: Histopathology of tumor regression after intralesional injection of Mycobacterium bovis. I. Tumor growth and metastasis. J Natl Cancer Inst 1972;48:1441–1449.
5.
Hanna MG, Zbar B, Rapp HJ: Histopathology of tumor regression after intralesional injection of Mycobacterium bovis. II. Comparative effects of Vaccinia virus, oxazolone, and turpentine. J Natl Cancer Inst 1972;48:1697–1707.
6.
Hanna MG, Snodgrass MJ, Zbar B, Rapp HJ: Histopathology of tumor regression after intralesional injection of Mycobacterum bovis. III. Development of immunity to tumor cells and BCG. J Natl Cancer Inst 1973;51:1897.
7.
Baldwin RW, Pimm M: BCG and Cancer. Adv Cancer Res 1978;28:91–147.
8.
Bartlett GL, Zbar B, Rapp HJ: Suppression of murine tumor growth by immune reaction to the bacillus Calmette-Guérin strain of Mycobacterium bovis. J Natl Cancer Inst 1972;48:245–257.
9.
Bartlett GL, Kreider JW, Purnell DM, Katsilas DC: Augmentation of immunity to line 10 hepatoma by BCG. Comparison of different BCG preparations. Cancer 1980;46:488–496.
10.
Mathé G, Halle-Pannenko O, Bourut C: BCG in cancer immunotherapy. II. Results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis and immunotherapy. Natl Cancer Inst Monogr 1973;39:107–112.
11.
Sher NA, Pearson JW, Chaparas SD: Effect of three strains of BCG against a murine leukemia after drug therapy. J Natl Cancer Inst 1973;51:2001–2003.
12.
Sparks FC, O’Connell TX, Lee Y-Y: Adjuvant preoperative and postoperative immunochemotherapy for mammary adenocarcinoma in rats. Surg Forum 1973;24:118–121.
13.
Schamhart DH, de Boer EC, Bevers RF, Kurth K-H, Steerenberg PA: Mycobacterial adherence and BCG treatment of superficial bladder cancer. Prog Clin Biol Res 1992;378:75–80.
14.
Kavoussi LR, Brown EJ, Ritchey JK, Ratliff TL: Fibronectin-mediated Calmette-Guérin Bacillus attachment to murine bladder mucosa. Requirement of the expression of an antitumor response. J Clin Invest 1990;85:62–67.
15.
Ratliff TL, Kavoussi LR, Catalona WJ: Role of fibronectin in intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer. J Urol 1988;139:410–414.
16.
Ratliff TL, Palmer JO, McGarr JA, Brown EJ: Intravesical BCG therapy for murine bladder tumors: Initiation of the response by fibronectin-mediated attachment of BCG. Cancer Res 1987;47:1762–1766.
17.
Hudson MA, Ritchey JK, Catalona WJ, Brown EJ, Ratliff TL: Comparison of the fibronectin-binding ability and antitumor efficacy of various mycobacteria. Cancer Res 1990;50:3843–3847.
18.
Hudson MA, Brown EJ, Ritchey JK, Ratliff TL: Modulation of fibronectin-mediated bacillus Calmette-Guérin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res 1991;51:3726–3732.
19.
Guinan PD, Shaw M, Ray V: Histopathology of BCG and Thiotepa treated bladders. Urol Res 1986;14:211–215.
20.
Ratliff TL, Gillen DP, Catalona WJ: Requirement of a thymus-dependent immune response for BCG-mediated antitumor activity. J Urol 1987;137:155–158.
21.
Ratliff TL, Ritchey JK, Yuan JJJ, Andriole GL, Catalona WJ: T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 1993;150:1018–1023.
22.
Coley-Nauts H, Fowler GA, Bogatko FH: A review of the influence of bacterial infection and of bacterial products (Coleys toxins) on malignant tumors in man. Acta Med Scand 1953;276:5–14.
23.
Freund J: The mode of action of immunologic adjuvants. Adv Tuberc Res 1956;7:130–148.
24.
Mathé G, Amiel J, Schwarzenberg L, Schneider M, Catton A, Schlumberger J: Acute immunotherapy for acute lymphoblastic leukemia. Lancet 1969;1:679–699.
25.
Coe JE, Feldman JD: Extracutaneous delayed hypersensitivity, particularly in the guinea pig bladder. Immunol 1966;10:127–136.
26.
Morales A, Eidinger D, Bruce AW: Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 1976;116:180–183.
27.
Connolly JG: Re: Immunotherapy of superficial bladder cancer. Letter to the Editor. J Urol 1983;130:368.
28.
Böhle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad H-D: Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 1990;144:53–58.
29.
Böhle A, Busemann E, Gerdes J, Ulmer AJ, Flad H-D, Jocham D: Long-term immunobiological effects of intravesical bacillus Calmette-Guérin against bladder carcinoma recurrences; in Brown F, Revillard RP (eds): Developments in Biological Standardization. Standardization of the Immunopharmacology of Natural and Synthetic Immunomodulators. Basel, Karger, 1992, pp 199–209.
30.
Böhle A, Nowc C, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG: Elevations of cytokines interleukin-1, interleukin-2, and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy. J Urol 1990;144:59–64.
31.
Jackson AM, Alexandroff AB, McIntyre M, Esuvaranathan K, James K, Chisholm GD: Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy. J Clin Pathol 1994;47:309–312.
32.
El-Demiry MIM, Smith G, Ritchie AWS, James K, Cumming JA, Hargreave TB: Local immune responses after intravesical BCG treatment for carcinoma in situ. Brit J Urol 1987;60:543–548.
33.
Papadimitriou JM, Spector WG: The ultrastructure of high- and low-turnover inflammatory granulomata. J Pathol 1982;106:37.
34.
de Boer EC, de Jong WH, van der Meijden APM, Steerenberg PA, Witjes F, Vegt PDJ: Presence of activated lymphocytes in the urine of patients after intravesical immunotherapy with bacillus Calmette-Guérin. Cancer Immunol Immunother 1991;33:411–416.
35.
de Boer EC, de Jong WH, van der Meijden APM, Steerenberg PA, Witjes F, Vegt PDJ: Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. Urol Res 1991;19:45–50.
36.
Jackson AM, Alexandroff AB, Kelly RW, Skibinska A, Esuvaranathan K, Prescott S: Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol 1995;99:369–375.
37.
Jackson AM, Prescott S, Hawkyard SJ, James K, Chisholm GD: The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical Evans BCG therapy. Cancer Immunol Immunother 1993;36:25–30.
38.
de Boer EC, de Jong WH, Steerenberg PA, van der Meijden APM, Aarden AL: Leukocytes and cytokines in the urine of superficial bladder cancer patients after immunotherapy with BCG. In Vivo 1991;5:671–677.
39.
de Boer EC, de Jong WH, Steerenberg PA, Aarden LA, Tetteroo E, de Groot ER: Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumor necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother 1992;34:306–312.
40.
de Boer EC, Somogyi L, de Ruiter GJW, de Reijke TM, Kurth K-H, Schamhart DH: Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol Res 1997;25:31–34.
41.
de Boer EC, Steerenberg PA, van der Meijden APM, van Klingeren B, de Jong WH, Elgersma A: Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig. J Urol 1992;148:1577–1582.
42.
Kimball ES, Pickeral SF, Oppenheim JJ, Rossio JL: Interleukin 1 activity in normal human urine. J Immunol 1984;133:256–260.
43.
Donohue JH, Rosenberg SA: The fate of interleukin-2 after in vivo administration. J Immunol 1983;130:2203–2208.
44.
Rosenberg SA: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889–897.
45.
Adolf GR, Lamche HR: Highly sensitive enzyme immunoassay for human lymphotoxin (tumor necrosis factor β) in serum. J Immunol Meth 1990; 130:177–185.
46.
Ernst M, Lange A, Flad H-D, Havel A, Ennen J, Ulmer AJ: Dissociation of responses measured by natural cytotoxicity and chemiluminescence. Eur J Immunol 1984;14:634–639.
47.
Lamm DL, Thor DE, Winters WD, Stogdill V, Radwin H: BCG immunotherapy of bladder cancer: Inhibition of tumor recurrence and associated immune responses. Cancer 1981;48:82–88.
48.
van der Sloot E, Kuster S, Böhle A, Braun J, Wood WG: Towards an understanding of the mode of action of bacillus Calmette-Guérin-therapy in bladder cancer treatment, especially with regard to the role of fibronectin. Eur J Clin Chem Clin Biochem 1992;30:503–511.
49.
Zlotta AR, Drowart A, Van Vooren JP, Simon J, Schulman CC, Huygen K: Evolution of cellular and humoral response against tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer. Acta Urol Belg 1994;62:63–68.
50.
Zlotta AR, Drowart A, Huygen K, De Bruyn J, Shekarsarai H, Decock M: Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer. Clin Exp Immunol 1997;109:157–165.
51.
Zlotta AR, Drowart A, van Vooren J-P, de Cock M, Pirson M, Palfliet K: Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of Bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer. J Urol 1997;157:492–498.
52.
Böhle A, van der Sloot E, Richter E, Gerdes J, Wood WG, Jocham D: Binding to Fibronectin (FN) – a prerequisite step? Investigations on the role of FN in intravesical BCG immunotherapy; in Thüroff JW, Miller K, Jocham D (eds): Investigative Urology 5. Weinheim, Chapman and Hall, 1994, pp 100–104.
53.
de Boer EC, DeReijke TM, Schamhart DHJ, Vos PCN, Kurth K-H: Increased urinary albumin indicating urothelial leakage following intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. Urol Res 1993;21:423–427.
54.
Jackson AM, James K: Understanding the most successful immunotherapy for cancer. The Immunologist 1994;2:208–215.
55.
de Reijke TM, de Boer EC, Kurth K-H, Schamhart DHJ: Urinary cytokines during intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer: Processing, stability and prognostic value. J Urol 1996;155:477–482.
56.
Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF: Intravesical Evans strain BCG therapy: Quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992;147:1636–1642.
57.
Bassi P, Milani C, Meneghini A, Garbeglio A, Aragona F, Zattoni F: Clinical value of pathologic changes after intravesical BCG therapy of superficial bladder cancer. Urology 1992;40:175–179.
58.
Hawkyard SJ, Jackson AM, James K, Prescott S, Smyth JF, Chisholm GD: The inhibitory effects of interferon gamma on the growth of bladder cancer cells. J Urol 1992;147:1399–1403.
59.
Thanhäuser A, Böhle A, Flad H-D, Ernst M, Mattern T, Ulmer AJ: Induction of bacillus Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro. Cancer Immunol Immunother 1993;37:105–111.
60.
Wang M-H, Flad H-D, Böhle A, Chen Y-Q, Ulmer AJ: Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines. Immunol Lett 1991;27:191–198.
61.
Böhle A, Wang M-H, Flad H-D, Ulmer AJ: In vitro cellular cytotoxicity against human bladder carcinoma cell lines; in Jocham D, Thüroff JW, Rübben H (eds): Investigative Urology 4. Berlin, Springer, 1991, pp 131–139.
62.
Schäfer I, Braasch H, Wang S, Ulmer AJ, Flad H-D, Jocham D: The cytotoxicity of natural killer cells ex-vivo against isolated autologous human urothelial bladder tumor cells (abstract). Urol Res 1995;23:286.
63.
Wang AM, Chen Y-Q, Gercken J, Ernst M, Böhle A, Flad H-D: Specific activation of human peripheral blood τ/δ+T lymphocytes by sonicated antigens of mycobacterium tuberculosis: Role in vitro in killing human bladder carcinoma cell lines. Scand J Immunol 1993;38:239–246.
64.
Jackson AM, Alexandrov AB, Prescott S, James K, Chisholm GD: Role of adhesion molecules in lymphokine-activated killer cell killing of bladder cancer cells: Further evidence for a third ligand for leucocyte function-associated antigen-1. Immunology 1992;76:286–291.
65.
Jackson AM, Hawkyard SJ, Prescott S, Ritchie AWS, James K, Chisholm GD: An investigation of factors influencing the in vitro induction of LAK activity against a variety of human bladder cancer cell lines. J Urol 1992;147:207–211.
66.
Böhle A, Durek C, Schäfer I, Brandau S, Ulmer AJ, Flad H-D: Die BCG-aktivierte Killerzelle: Untersuchung spezifischer Erkennungs- und Tötungsmechanismen zur Charakterisierung des Wirkprinzips der intravesikalen Immuntherapie mit Bacillus Calmette-Guérin. Akt Urol 1998;29:175–187.
67.
Böhle A, Thanhäuser A, Ulmer AJ, Ernst M, Flad H-D, Jocham D: Dissecting the immunobiological effects of bacillus Calmette-Guérin (BCG) in vitro: Evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J Urol 1993;150:1932–1937.
68.
Tawab NA, Brandau S, Maille P, Zamattio S, Böhle A: Evolution and clinical significance of BAK cell-mediated cytotoxicity against bladder tumor cell lines during intravesical treatment of superficial bladder cancer (abstract). Eur Urol 1998;34:245–302.
69.
Thanhäuser A, Böhle A, Schneider B, Reiling N, Mattern T, Ernst M: The induction of bacillus Calmette-Guérin-activated killer cells requires the presence of monocytes/macrophages and T-helper type 1 cells. Cancer Immunol Immunother 1995;40:103–108.
70.
Böhle A, Thanhäuser A, Ulmer AJ, Mattern T, Ernst M, Flad H-D: On the mode of action of intravesical Bacillus Calmette-Guérin: In vitro characterization of BCG-activated killer cells. Urol Res 1994;22:185–190.
71.
Coplen DE, Marcus MD, Myers JA, Ratliff TL, Catalona WJ: Long-term follow-up of patients treated with 1 or 2, 6-week courses of intravesical Bacillus Calmette-Guérin: Analysis of possible predictors of response free of tumor. J Urol 1990; 144:652–657.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.